annual cash & cash equivalents:
$9.99B+$3.91B(+64.19%)Summary
- As of today (June 22, 2025), GILD annual cash & cash equivalents is $9.99 billion, with the most recent change of +$3.91 billion (+64.19%) on December 31, 2024.
- During the last 3 years, GILD annual cash & cash equivalents has risen by +$4.65 billion (+87.17%).
- GILD annual cash & cash equivalents is now -44.31% below its all-time high of $17.94 billion, reached on December 31, 2018.
Performance
GILD Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$7.93B-$2.06B(-20.67%)Summary
- As of today (June 22, 2025), GILD quarterly cash & cash equivalents is $7.93 billion, with the most recent change of -$2.06 billion (-20.67%) on March 1, 2025.
- Over the past year, GILD quarterly cash & cash equivalents has increased by +$3.21 billion (+67.99%).
- GILD quarterly cash & cash equivalents is now -55.82% below its all-time high of $17.94 billion, reached on December 31, 2018.
Performance
GILD quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
GILD Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +64.2% | +68.0% |
| 3 y3 years | +87.2% | +84.5% |
| 5 y5 years | -14.1% | -21.1% |
GILD Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +87.2% | -20.7% | +185.9% |
| 5 y | 5-year | -14.1% | +87.2% | -38.5% | +185.9% |
| alltime | all time | -44.3% | >+9999.0% | -55.8% | >+9999.0% |
GILD Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $7.93B(-20.7%) |
| Dec 2024 | $9.99B(+64.2%) | $9.99B(+98.4%) |
| Sep 2024 | - | $5.04B(+81.7%) |
| Jun 2024 | - | $2.77B(-41.2%) |
| Mar 2024 | - | $4.72B(-22.5%) |
| Dec 2023 | $6.08B(+12.4%) | $6.08B(+6.7%) |
| Sep 2023 | - | $5.71B(+0.0%) |
| Jun 2023 | - | $5.70B(+15.6%) |
| Mar 2023 | - | $4.94B(-8.8%) |
| Dec 2022 | $5.41B(+1.4%) | $5.41B(+15.2%) |
| Sep 2022 | - | $4.70B(-0.8%) |
| Jun 2022 | - | $4.74B(+10.3%) |
| Mar 2022 | - | $4.30B(-19.5%) |
| Dec 2021 | $5.34B(-11.0%) | $5.34B(+22.4%) |
| Sep 2021 | - | $4.36B(-10.9%) |
| Jun 2021 | - | $4.89B(+20.4%) |
| Mar 2021 | - | $4.07B(-32.2%) |
| Dec 2020 | $6.00B(-48.4%) | $6.00B(-53.5%) |
| Sep 2020 | - | $12.89B(+91.0%) |
| Jun 2020 | - | $6.75B(-32.9%) |
| Mar 2020 | - | $10.05B(-13.6%) |
| Dec 2019 | $11.63B(-35.2%) | $11.63B(+22.8%) |
| Sep 2019 | - | $9.47B(-15.7%) |
| Jun 2019 | - | $11.24B(-33.6%) |
| Mar 2019 | - | $16.93B(-5.6%) |
| Dec 2018 | $17.94B(+136.4%) | $17.94B(+23.1%) |
| Sep 2018 | - | $14.57B(+10.1%) |
| Jun 2018 | - | $13.23B(+73.2%) |
| Mar 2018 | - | $7.64B(+0.7%) |
| Dec 2017 | $7.59B(-7.8%) | $7.59B(-34.1%) |
| Sep 2017 | - | $11.51B(+32.1%) |
| Jun 2017 | - | $8.71B(-15.3%) |
| Mar 2017 | - | $10.29B(+25.0%) |
| Dec 2016 | $8.23B(-36.0%) | $8.23B(-16.1%) |
| Sep 2016 | - | $9.81B(+51.3%) |
| Jun 2016 | - | $6.49B(+2.7%) |
| Mar 2016 | - | $6.32B(-50.9%) |
| Dec 2015 | $12.85B(+28.2%) | $12.85B(-8.0%) |
| Sep 2015 | - | $13.96B(+88.3%) |
| Jun 2015 | - | $7.42B(-30.3%) |
| Mar 2015 | - | $10.63B(+6.1%) |
| Dec 2014 | $10.03B(+374.5%) | $10.03B(+61.5%) |
| Sep 2014 | - | $6.21B(-28.9%) |
| Jun 2014 | - | $8.73B(+36.3%) |
| Mar 2014 | - | $6.40B(+203.1%) |
| Dec 2013 | $2.11B(+17.1%) | $2.11B(+5.1%) |
| Sep 2013 | - | $2.01B(-8.7%) |
| Jun 2013 | - | $2.20B(+18.1%) |
| Mar 2013 | - | $1.86B(+3.3%) |
| Dec 2012 | $1.80B(-81.8%) | $1.80B(+16.3%) |
| Sep 2012 | - | $1.55B(-4.6%) |
| Jun 2012 | - | $1.63B(+12.0%) |
| Mar 2012 | - | $1.45B(-85.3%) |
| Dec 2011 | $9.88B(+988.7%) | $9.88B(+986.9%) |
| Sep 2011 | - | $909.36M(+0.4%) |
| Jun 2011 | - | $905.78M(-50.7%) |
| Mar 2011 | - | $1.84B(+102.2%) |
| Dec 2010 | $907.88M(-28.7%) | $907.88M(-11.3%) |
| Sep 2010 | - | $1.02B(-31.0%) |
| Jun 2010 | - | $1.48B(+58.3%) |
| Mar 2010 | - | $936.88M(-26.4%) |
| Dec 2009 | $1.27B(-12.8%) | $1.27B(+24.2%) |
| Sep 2009 | - | $1.02B(-1.6%) |
| Jun 2009 | - | $1.04B(-37.4%) |
| Mar 2009 | - | $1.66B(+14.0%) |
| Dec 2008 | $1.46B | $1.46B(+20.7%) |
| Sep 2008 | - | $1.21B(+8.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2008 | - | $1.12B(+54.9%) |
| Mar 2008 | - | $722.88M(-25.3%) |
| Dec 2007 | $968.09M(+18.6%) | $968.09M(+65.7%) |
| Sep 2007 | - | $584.13M(-16.7%) |
| Jun 2007 | - | $701.65M(-3.8%) |
| Mar 2007 | - | $729.14M(-10.6%) |
| Dec 2006 | $816.01M(+15.3%) | $816.01M(+45.8%) |
| Sep 2006 | - | $559.58M(-36.7%) |
| Jun 2006 | - | $884.45M(+229.2%) |
| Mar 2006 | - | $268.68M(-62.0%) |
| Dec 2005 | $707.91M(+152.0%) | $707.91M(+19.4%) |
| Sep 2005 | - | $592.72M(-25.3%) |
| Jun 2005 | - | $793.62M(+181.5%) |
| Mar 2005 | - | $281.94M(+0.4%) |
| Dec 2004 | $280.91M(+44.3%) | $280.91M(-6.8%) |
| Sep 2004 | - | $301.45M(+33.1%) |
| Jun 2004 | - | $226.56M(+45.6%) |
| Mar 2004 | - | $155.59M(-20.1%) |
| Dec 2003 | $194.72M(-68.4%) | $194.72M(+88.5%) |
| Sep 2003 | - | $103.32M(-39.0%) |
| Jun 2003 | - | $169.35M(+44.2%) |
| Mar 2003 | - | $117.48M(-81.0%) |
| Dec 2002 | $616.93M(+399.6%) | $616.93M(+407.3%) |
| Sep 2002 | - | $121.61M(-0.3%) |
| Jun 2002 | - | $122.01M(+6.0%) |
| Mar 2002 | - | $115.09M(-6.8%) |
| Dec 2001 | $123.49M(-37.4%) | $123.49M(+230.7%) |
| Sep 2001 | - | $37.35M(-20.4%) |
| Jun 2001 | - | $46.92M(-39.4%) |
| Mar 2001 | - | $77.40M(-60.8%) |
| Dec 2000 | $197.29M(+319.7%) | $197.29M(+354.9%) |
| Sep 2000 | - | $43.37M(+1.5%) |
| Jun 2000 | - | $42.74M(+14.6%) |
| Mar 2000 | - | $37.30M(-20.7%) |
| Dec 1999 | $47.01M(-53.5%) | $47.01M(-33.6%) |
| Sep 1999 | - | $70.80M(+56.3%) |
| Jun 1999 | - | $45.30M(-22.4%) |
| Mar 1999 | - | $58.40M(-42.2%) |
| Dec 1998 | $101.10M(+215.9%) | $101.10M(+134.0%) |
| Sep 1998 | - | $43.20M(+16.8%) |
| Jun 1998 | - | $37.00M(+7.9%) |
| Mar 1998 | - | $34.30M(+7.2%) |
| Dec 1997 | $32.00M(-75.8%) | $32.00M(-30.0%) |
| Sep 1997 | - | $45.70M(-67.1%) |
| Jun 1997 | - | $139.00M(+32.8%) |
| Mar 1997 | - | $104.70M(-20.7%) |
| Dec 1996 | $132.00M(+381.8%) | $132.00M(-15.4%) |
| Sep 1996 | - | $156.00M(-14.7%) |
| Jun 1996 | - | $182.90M(+270.2%) |
| Mar 1996 | - | $49.40M(-31.8%) |
| Dec 1995 | $27.40M(-9.9%) | - |
| Sep 1995 | - | $72.40M(+751.8%) |
| Jun 1995 | - | $8.50M(-72.0%) |
| Mar 1995 | - | $30.40M(+98.7%) |
| Mar 1995 | $30.40M(+133.8%) | - |
| Dec 1994 | - | $15.30M(-42.5%) |
| Sep 1994 | - | $26.60M(-39.1%) |
| Jun 1994 | - | $43.70M(+236.2%) |
| Mar 1994 | $13.00M(+519.0%) | $13.00M(+51.2%) |
| Dec 1993 | - | $8.60M(+309.5%) |
| Sep 1993 | - | $2.10M(-40.0%) |
| Jun 1993 | - | $3.50M(+66.7%) |
| Mar 1993 | $2.10M(-97.6%) | $2.10M(-95.6%) |
| Dec 1992 | - | $47.80M(+1978.3%) |
| Sep 1992 | - | $2.30M(-87.2%) |
| Jun 1992 | - | $17.90M(-79.6%) |
| Mar 1992 | $87.90M(+753.4%) | $87.90M(+753.4%) |
| Mar 1991 | $10.30M | $10.30M |
FAQ
- What is Gilead Sciences annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Gilead Sciences?
- What is Gilead Sciences annual cash & cash equivalents year-on-year change?
- What is Gilead Sciences quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Gilead Sciences?
- What is Gilead Sciences quarterly cash & cash equivalents year-on-year change?
What is Gilead Sciences annual cash & cash equivalents?
The current annual cash & cash equivalents of GILD is $9.99B
What is the all time high annual cash & cash equivalents for Gilead Sciences?
Gilead Sciences all-time high annual cash & cash equivalents is $17.94B
What is Gilead Sciences annual cash & cash equivalents year-on-year change?
Over the past year, GILD annual cash & cash equivalents has changed by +$3.91B (+64.19%)
What is Gilead Sciences quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of GILD is $7.93B
What is the all time high quarterly cash & cash equivalents for Gilead Sciences?
Gilead Sciences all-time high quarterly cash & cash equivalents is $17.94B
What is Gilead Sciences quarterly cash & cash equivalents year-on-year change?
Over the past year, GILD quarterly cash & cash equivalents has changed by +$3.21B (+67.99%)